HYFTMindWalk Holdings Corp.
$1.55
$0.06
(4.03%)
Closed $1.55
$0.0471
(3.04%)
After Hours
EarningsJul 14
Mkt Cap$69.6M
Vol413,475.00
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It PR Newswire NEW YORK, June 16, 2026 Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful...
PR Newswire
Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge
Biotechnology and healthcare innovation dominated investor conversations today as multiple companies delivered meaningful corporate, clinical, regulatory, and commercialization updates. From artificial intelligence-powered drug discovery platforms to neuro-oncology, regenerative medicine, wound care technologies, and autoimmune disease therapies, investors focused on companies that could potentially benefit from major industry trends while advancing important milestones of their own. $CUPR, $HYFT, $NTHI, $RGNT, $GELS, $SABS
24-7 Market News
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
MindWalk Holdings Corp. (MindWalk) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel...
Business Wire
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ, a Biological Context Layer for AI Drug Discovery
MindWalk Holdings Corp. (MindWalk) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery...
Business Wire
MindWalk's Preclinical Dengue Data Support a HYFT Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
MindWalk Holdings Corp. (Nasdaq: HYFT) today reported preclinical dengue data that support a computational prediction its HYFT platform generated before any animal was immunized. HYFT computationally identified a candidate pan-serotype structural target on the dengue virus. The subsequent...
Business Wire
MindWalk Holdings Deploys Pandemic Response Platform via HYFT Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT biological pattern system and LensAI platform purpose-built for outbreak...
Business Wire
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
Business Wire
MindWalk (NASDAQ:HYFT) Stock Rating Upgraded by JonesTrading
JonesTrading raised MindWalk to a "strong-buy" rating in a research note on Wednesday...
MarketBeat
MindWalk (NASDAQ:HYFT) Now Covered by JonesTrading
JonesTrading assumed coverage on shares of MindWalk in a research report on Thursday. They issued a "buy" rating and a $5.00 price target on the stock...
MarketBeat
MindWalk (NASDAQ:HYFT) Stock Price Up 1.9% - Should You Buy?
MindWalk (NASDAQ:HYFT) Stock Price Up 1.9% - Still a Buy...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest HYFT News
ViewThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
PR Newswire
Why Traders Are Piling into These Emerging Healthcare Names as New Catalysts Emerge
24-7 Market News
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
Business Wire
Advertisement|Remove ads.